LFA-1 Inhibitors
1 drugsAbout LFA-1
LFA-1 (Leukocyte Function-associated Antigen 1) is a cell surface protein involved in cell adhesion and immune cell interactions, playing a crucial role in immune processes.
LFA-1 is a pharmacological target for immune-related conditions, but currently lacks genetic evidence directly linking it to specific diseases.
XIIDRA, a small molecule drug approved in 2016, targets LFA-1 for ophthalmic indications, and is marketed by BAUSCH AND LOMB INC.
Top LFA-1 Drugs
BAUSCH AND LOMB INC is the only company with an approved drug targeting LFA-1.
The market is highly concentrated, indicating potential entry barriers or limited commercial opportunity.
LFA-1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets LFA-1, using small molecule modality.
Explore antibody or protein-based modalities to differentiate from existing small molecule approach.
LFA-1 Clinical Trials 26 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on LFA-1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 5 | 5 | 0 | 0 | 100% |
| Phase 3 | 5 | 4 | 1 | 0 | 80% |
| Phase 4 | 14 | 7 | 5 | 2 | 58% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
LFA-1 Drug Approval Timeline (2016 - 2016)
The first and only drug targeting LFA-1, XIIDRA, was approved in 2016.
The approval timeline shows a lack of recent activity, suggesting a potentially saturated market or challenges in developing new LFA-1 therapeutics.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 19 (8 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on LFA-1. A trial counts if an approved drug acting on LFA-1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.